IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats

Prostate

Volumn 67, Issue 7, 2007, Pages 701-713

  Rajeshkumar, N V ^b   Matwyshyn, George ^b   Gulati, Anil ^a  

^a MIDWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

5 flurouracil; Chemotherapy; Doxorubicin; Endothelin; IRL 1620; Tumor blood flow

Indexed keywords

DOXORUBICIN; FLUOROURACIL; PLACEBO; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE];

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BODY WEIGHT; DOXORUBICIN; ENDOTHELINS; FLUOROURACIL; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; RECEPTOR, ENDOTHELIN B; VASODILATION; VASODILATOR AGENTS;

EID: 34248209225     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20556     Document Type: Article

References (76)

1. Sachdeva MS. Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs 1998;7:1849-1864.
2. Collier D, Soloway MS. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma. Urology 1976;8:459-464.
3. Soloway MS, Shippel RM, Ikard M. Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 1979;122:637-639.
4. Lin CC, Hsu CH, Chen J, Tsai TC, Cheng AL, Pu YS. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res 2001;21:1385-1390.
5. Smalley RV, Bartolucci AA, Hemstreet G, Hester M. A Phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 1981;125:191-195.
6. Chen CT, Au JL, Wientjes MG. Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res 1998;4:277-282.
7. Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004;3:165-173.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
9. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
10. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797-9800.
11. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77-87.
12. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981;67:663-669.
13. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, Taylor I. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 2001;85:1759-1763.
14. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003;3:110-116.
15. Bagnato A, Natali PG. Targeting endothelin axis in cancer. Cancer Treat Res 2004;119:293-314.
16. Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, Oda K, Urade Y, Inui T, Yamamura T, Okada T. A potent and specific agonist, Suc-[Glu9, Ala11, 15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun 1992;184:953-959.
17. Rajeshkumar NV, Rai A, Gulati A. Endothelin B receptor agonist, IRL-1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 2005;94:237-247.
18. Okada M, Nishikibe M. BQ-788, a selective endothelin ET(B) receptor antagonist. Cardiovasc Drug Rev 2002;20:53-66.
19. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-949.
20. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000;6:1664-1670.
21. Dawson LA, Maitland NJ, Berry P, Turner AJ, Usmani BA. Expression and localization of endothelin-converting enzyme-1 in human prostate cancer. Exp Biol Med (Maywood) 2006;231:1106-1110.
22. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165:1033-1036.
23. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12:6296s-6300s.
24. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
25. Gaddipati JP, Rajeshkumar NV, Thangapazham RL, Sharma A, Warren J, Mog SR, Singh AK, Maheshwari RK. Protective effect of a polyherbal preparation, Brahma rasayana against tumor growth and lung metastasis in rat prostate model system. J Exp Ther Oncol 2004;4:203-212.
26. Rai A, Gulati A. Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 2003;51:21-28.
27. Reddy LH, Murthy RS. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004;148:161-166.
28. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002;126:131-141.
29. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, Sjoquist M, Ahlstrom H, Reed RK, Rubin K. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. Faseb J 2003;17:1756-1758.
30. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864.
31. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
32. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
33. Jimeno A, Carducci M. Atrasentan: Targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631-1640.
34. Jimeno A, Carducci M. Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5:419-427.
35. Murphy G. Atrasentan for metastatic hormone refractory prostate cancer. Issues Emerg Health Technol 2005; 1-4.
36. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9.
37. Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 2005;15:157-162.
38. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer - Has there been real progress in the past decade? Eur J Cancer 2005;41:941-953.
39. Zee-Cheng RK, Cheng CC. Delivery of anticancer drugs. Methods Find Exp Clin Pharmacol 1989;11:439-529.
40. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005;4:363-374.
41. Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N Engl J Med 1998;339:472-474.
42. Molema G, Meijer DK, de Leij LF. Tumor vasculature targeted therapies: Getting the players organized. Biochem Pharmacol 1998;55:1939-1945.
43. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004;25:536-542.
44. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
45. Molema G, de Leij LF, Meijer DK. Tumor vascular endothelium: Barrier or target in tumor directed drug delivery and immunotherapy. Pharm Res 1997;14:2-10.
46. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
47. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-435.
48. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446.
49. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
50. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6256.
51. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
52. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
53. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
54. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature 2003;423:593-595.
55. Steeg PS. Angiogenesis inhibitors: Motivators of metastasis? Nat Med 2003;9:822-823.
56. Ansiaux R, Baudelet C, Cron GO, Segers J, Dessy C, Martinive P, De Wever J, Verrax J, Wauthier V, Beghein N, Gregoire V, Buc Calderon P, Feron O, Gallez B. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006;12:1276-1283.
57. Jirtle RL. Chemical modification of tumour blood flow. Int J Hyperthermia 1988;4:355-371.
58. Jain RK. Determinants of rumor blood flow: A review. Cancer Res 1988;48:2641-2658.
59. Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: Current status and future directions. Semin Radiat Oncol 1998;8:151-163.
60. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
61. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature 2000;405:139-141.
62. Sudjarwo SA, Hori M, Tanaka T, Matsuda Y, Okada T, Karaki H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 1994;200:627-633.
63. Bell KM, Chaplin DJ, Poole BA, Prise VE, Tozer GM. Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer 1999;80:295-302.
64. Cemazar M, Wilson I, Prise VE, Bell KM, Hill SA, Tozer GM. The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: Potential for selective tumour blood flow modification. Br J Cancer 2005;93:98-106.
65. Bell KM, Prise VE, Chaplin DJ, Tozer GM. Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl 1996;27:S161-S163.
66. Liu JJ, Chen JR, Buxton BF. Unique response of human arteries to endothelin B receptor agonist and antagonist. Clin Sci (Lond) 1996;90:91-96.
67. Feger GI, Schilling L, Ehrenreich H, Wahl M. Endothelium-dependent relaxation counteracting the contractile action of endothelin-1 is partly due to ETB receptor activation. Res Exp Med (Berl) 1997;196:327-337.
68. Chen HS, Gross JF. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980;64:31-40.
69. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
70. Herrmann E, Bogemann M, Bierer S, Eltze E, Hertle L, Wulfing C. The endothelin axis in urologic tumors: Mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther 2006;6:73-81.
71. Watanabe M, Tateishi T, Takezawa N, Tanaka M, Kumai T, Nakaya S, Kobayashi S. Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol 2001;47:250-254.
72. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002;62:2390-2397.
73. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer 2000;87:276-282.
74. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 1996;149:59-71.
75. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-6392.
76. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-284.